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Transglutaminases are ubiquitous enzymes which catalyze posttranslationalmodiﬁcations of proteins.Recently, transglutaminase-
catalyzed post-translational modiﬁcation of proteins has been shown to be involved in the molecular mechanisms responsible
for human diseases. Transglutaminase activity has been hypothesized to be involved also in the pathogenetic mechanisms
responsible for several human neurodegenerative diseases. Alzheimer’s disease and other neurodegenerative diseases, such as
Parkinson’s disease, supranuclear palsy, Huntington’s disease, and other polyglutamine diseases, are characterized in part by
aberrant cerebral transglutaminase activity and by increased cross-linked proteins in aﬀected brains. This paper focuses on the
possible molecular mechanisms by which transglutaminase activity could be involved in the pathogenesis of Alzheimer’s disease
and other neurodegenerative diseases, and on the possible therapeutic eﬀects of selective transglutaminase inhibitors for the cure
of patients with diseases characterized by aberrant transglutaminase activity.
1. Biochemistry of the Transglutaminases
Transglutaminases (TGs, E.C. 2.3.2.13) are a family of enz-
ymes (Table 1) which catalyze irreversible posttranslational
modiﬁcations of proteins. Examples of TG-catalyzed reac-
tions include (I) acyl transfer between the γ-carboxamide
group of a protein/polypeptide glutaminyl residue and the
ε-amino group of a protein/polypeptide lysyl residue; (II)
attachment of a polyamine to the γ-carboxamide of a
glutaminyl residue; (III) deamidation of the γ-carboxamide
group of a protein/polypeptide glutaminyl residue (Figure 1)
[1, 2]. The reactions catalyzed by TGs occur by a two-step
mechanism (Figure 2). The transamidating activity of TGs is
activated by the binding of Ca2+, which exposes an active-
site cysteine residue. This cysteine residue reacts with the
γ-carboxamide group of an incoming glutaminyl residue
of a protein/peptide substrate to yield a thioacyl-enzyme
intermediate and ammonia (Figure 2, Step 1). The thioacyl-
enzymeintermediatethenreactswithanucleophilic primary
amine substrate, resulting in the covalent attachment of the
amine-containingdonortothesubstrateglutaminylacceptor
and regeneration of the cysteinyl residue at the active site
(Figure 2, Step 2). If the primary amine is donated by the
ε-amino group of a lysyl residue in a protein/polypeptide,
an Nε-(γ-L-glutamyl)-L-lysine (GGEL) isopeptide bond is
formed (Figure 1, example (a)). On the other hand, if
a polyamine or another primary amine (e.g., histamine)
acts as the amine donor, a γ-glutamylpolyamine (or γ-
glutamylamine) residue is formed (Figure 1, example (b)).
It is also possible for a polyamine to act as an N,N-bis-
(γ-L-glutamyl) polyamine bridge between two glutaminyl
acceptor residues either on the same protein/polypeptide
or between two proteins/polypeptides [3]. If there is no
primary amine present, water may act as the attacking
nucleophile, resulting in the deamidation of glutaminyl
residues to glutamyl residues (Figure 1, example (c)). It is
worthwhile noting that two of these reactions, in particular,
the deamidation of peptides obtained from the digestion
of the gliadin, a protein present in wheat, and the Nε-(γ-
L-glutamyl)-L-lysine (GGEL) isopeptide formation between
these peptides and “tissue” transglutaminase (TG2 or tTG),
have been recently shown to cause the formation of new
antigenic epitopes which are responsible of immunological
reactions during the celiac disease (CD), one of the most2 International Journal of Alzheimer’s Disease
Table 1: TG enzymes and their biological functions when known.
TG Physiological role Gene map location Reference
Factor XIIIa Blood clotting 6p24-25 [10]
TG 1 (Keratinocyte TG, kTG) Skin diﬀerentiation 14q11.2 [11]
TG 2 (Tissue TG, tTG, cTG) Apoptosis, cell adhesion, signal transduction 20q11-12 [12]
TG 3 (Epidermal TG, eTG) Hair follicle diﬀerentiation 20p11.2 [13]
TG 4 (Prostate TG, pTG) Suppression of sperm immunogenicity 3q21-2 [14]
TG 5 (TG X) Epidermal diﬀerentiation 15q15.2 [15]
TG 6 (TG Y) Unknown function 20p13 [15]
TG 7 (TG Z) Unknown function 15q15.2 [15]
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Figure 1: Transglutaminase-catalyzed reactions. Examples of TG-catalyzed reactions: (a) acyl transfer between the γ-carboxamide group of
a protein/polypeptide glutaminyl residue and the ε-amino group of a protein/polypeptide lysyl residue; (b) attachment of a polyamine to
the carboxamide group of a glutaminyl residue; (c) deamidation of the γ-carboxamide group of a protein/polypeptide glutaminyl residue.
common human autoimmune diseases [4, 5]. The reactions
catalyzed by TGs occur with little change in free energy
and hence should theoretically be reversible. However, under
physiological conditions the cross linking reactions catalyzed
by TGs are usually irreversible. This irreversibility partly
results from the metabolic removal of ammonia from the
system and from thermodynamic considerations resulting
from altered protein conformation. Some scientiﬁc reports
suggest that TGs may be able to catalyze the hydrolysis of
Nε-(γ-L-glutamyl)-L-lysine cross-links (GGEL) isopeptide
bonds in some soluble cross-linked proteins. Furthermore,
it is likely that TGs can catalyze the exchange of polyamines
onto proteins [2]. In some TGs, other catalytic activities,
such as the ability to hydrolyze GTP (or ATP) into GDP
(or ADP) and inorganic phosphate, a protein disulﬁde
isomerase activity, a serine/threonine kinase activity, and an
esteriﬁcation activity, are often present [6–9].
2. Multiple Biological Activitiesof the
Transglutaminases
Experimental evidences indicate that some TGs are mul-
tifunctional proteins with distinct and regulated enzy-
matic activities. In fact, under physiological conditions, the
transamidation activity of TGs is latent [16], while other
activities, recently identiﬁed, could be present. For example,
in some pathophysiological states, when the concentration
of Ca2+ increases, the crosslinking activity of TGs mayInternational Journal of Alzheimer’s Disease 3
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Figure 2: Schematic representation of a two-step transglutaminase
r e a c t i o n .S t e p1 :I nt h ep r e s e n c eo fC a 2+, the active-site cysteine
residue reacts with the γ-carboxamide group of an incoming
glutaminylresidueofaprotein/peptidesubstratetoyieldathioacyl-
enzyme intermediate and ammonia. Step 2: The thioacyl-enzyme
intermediate reacts with a nucleophilic primary amine substrate,
resulting in the covalent attachment of the amine-containing
donor to the substrate glutaminyl acceptor and regeneration of the
cysteinyl residue at the active site. If the primary amine is donated
by the ε-amino group of a lysyl residue in a protein/polypeptide, an
Nε-(γ-L-glutamyl)-L-lysine (GGEL) isopeptide bond is formed.
contribute to important biological processes. As previously
described, one of the most intriguing properties of some
TGs, such as TG2, is the ability to bind and hydrolyze GTP
and, furthermore, to bind to GTP and Ca2+.G T Pa n dC a 2+
regulate its enzymatic activities, including protein cross-
linking, in a reciprocal manner; the binding of Ca2+ inhibits
GTP-binding and GTP-binding inhibits the transglutami-
nase cross-linking activity of the TG2 [6]. Interestingly, TG2
shows no sequence homology with heterotrimeric or low-
molecular-weight G-proteins, but there is evidence that TG2
(TG2/Ghα)isinvolvedinsignaltransduction,and,therefore,
TG2/Ghα should also be classiﬁed as a large molecular
weight G-protein. Other studies, along with ours, showed
that TG2/Ghα can mediate the activation of phospholipase C
(PLC) by the α1b-adrenergic receptor [17]a n dc a nm o d u l a t e
adenylyl cyclase activity [18]. TG2/Ghα can also mediate
the activation of the δ1 isoform of PLC and of maxi-
K channels [19]. Interestingly, the signaling function of
TG2/Ghα is preserved even with the mutagenic inactivation
of its crosslinking activity by the mutation of the active site
cysteine residue [20]. Evidence of a pathophysiological role
of the TGs in cell signaling, in disulﬁde isomerase activity,
and in other biological functions, is lacking to date.
3.MolecularBiology of the Transglutaminases
At least eight diﬀerent TGs, distributed in the human
body, have been identiﬁed (Table 1). Complex mechanisms
regulatingthegeneexpressionofTGs,bothattranscriptional
and translational levels, determine a complex butprecise dis-
tribution of these enzymes in a cell and/or a tissue [21]. Such
complex gene expression reﬂects the physiological roles that
these enzymes play in both the intracellular and extracellular
compartments. In the nervous system, for example, several
forms of TGs are simultaneously expressed [15, 22, 23].
Moreover,severalalternativesplicevariantsofTGs,mostlyin
the 3-end region, have been identiﬁed. Interestingly, some
of them are diﬀerently expressed in human pathologies,
such as Alzheimer’s disease (AD) [24]. On the basis of
their ubiquitous expression and their biological roles, we
may speculate that the absence of these enzymes would be
lethal. However, this does not always seem to be the case,
since, for example, null mutants of the TG2 are usually
phenotypically normal at birth [25]. This result may be
explained by the multiple expressions of other TG genes that
could be substituting the missing isoform.
Bioinformaticstudieshaveshownthattheprimarystruc-
turesofhumanTGssharesomeidentitiesinonlyfewregions,
such as the active site and the calcium-binding regions.
However, high sequence conservation and, therefore, a high
degree of preservation of residue secondary structure among
TG2, TG3, and FXIIIa indicate that these TGs all share four-
domain tertiary structures which could be similar to those of
other TGs [26].
4.TransglutaminasesandAlzheimer’s Disease
Numerous scientiﬁc reports suggest that TG activity is
involved in the pathogenesis of Alzheimer’s disease and other
neurodegenerative diseases. To date, however, deﬁnitive
experimental ﬁndings about the role of these enzymes in
the development of these neurological diseases have not yet
been obtained. Protein aggregates in aﬀected brain regions
are histopathological hallmarks of Alzheimer’s disease and
many other neurodegenerative diseases [27]. More than 20
years ago, Selkoe et al. [28] suggested that TG activity
might contribute to the formation of protein aggregates
in AD brain. In support of this hypothesis, tau protein
has been shown to be an excellent in vitro substrate of
TGs [29–32], and GGEL cross-links have been found in
the neuroﬁbrillary tangles and paired helical ﬁlaments of
AD brains [33, 34]. In addition to these experimental
ﬁndings, it has been shown that TGs and transglutaminase-
catalyzed cross-links colocalize with pathological lesions in
Alzheimer’s disease brain [34–36]. Interestingly, a recent
work showed the presence of bis γ-glutamyl putrescine in4 International Journal of Alzheimer’s Disease
human CSF, which was increased in Huntington’s disease
(HD) CSF [37]. These are important experimental data
which demonstrate that protein/peptides cross-links and
protein/peptides cross-linking by polyamines do indeed
occur in brain, and that these transglutaminase-catalyzed
reaction products are increased in AD and HD brains. More
recently, TG activity has been shown to induce amyloid β-
protein oligomerization and aggregationat physiologic levels
in vitro [38, 39]. By these molecular mechanisms, TGs could
contributetoADsymptomsandprogression[39].Moreover,
there is evidence that TGs also contribute to the formation of
proteinaceous deposits in Parkinson’s disease (PD) [40, 41]
and in supranuclear palsy [42, 43]. To support the role of
the TG activity in the pathogenesis of neurodegenerative
diseases, expanded polyglutamine domains, present in HD
and other neurodegenerative diseases caused by a CAG
expansion in the aﬀected gene (Table 2)[ 44], have been
reported to be substrates of TG2 in vitro [45–47]. Therefore,
aberrant TG activity could contribute to the pathogenesis
of neurodegenerative diseases, including Alzheimer’s disease
and other neurodegenerative diseases, by diﬀerent molecular
mechanisms, as described in Figure 3. However, although
all these studies suggest the possible involvement of the
TGs in the formation of deposits of protein aggregates in
neurodegenerative diseases, they do not indicate whether
aberrant TG activity per se directly determines the disease’s
progression. In support of the hypothesis of a pathophys-
iological role for protein aggregates in neurodegenerative
diseases, it is worth noting that the aggregate formation
has been shown to inhibit the proteasome degradation of
expanded polyglutamine proteins [48].
5.Transglutaminases as Potential Therapeutic
Targets of Neurodegenerative Diseases
Since up to now there have been no long-term eﬀective
treatments for human neurodegenerative diseases, then the
possibility that selective TG inhibitors may be of clinical
beneﬁt has been seriously considered. In this respect, some
encouraging results have been obtained with TG inhibitors
in preliminary studies with diﬀerent biological models of
CAG-expansion diseases. For example, cystamine (Figure 4)
is a potent in vitro inhibitor of enzymes that require an
unmodiﬁed cysteine at the active site [59]. Inasmuch as
TGs contain a crucial active-site cysteine, cystamine has the
potential to inhibit these enzymes by disulﬁde interchange
reactions. A disulﬁde interchange reaction results in the
formation of cysteamine and a cysteamine-cysteine mixed
disulﬁde residue at the active site. Recent studies have shown
that cystamine decreases the number of protein inclusions in
transfected cells expressing the atrophin protein containing
a pathological-length polyglutamine domain, responsible
for the Dentato-Rubro-Pallido-Luysian Atrophy (DRPLA)
[60]. In other studies, cystamine administration to HD-
transgenic mice resulted in an increase in life expectancy and
amelioration of neurological symptoms [61, 62]. Neuronal
inclusions were decreased in one of these studies [62].
Although all these scientiﬁc reports seem to support the
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hypothesis of a direct role of TG activity in the pathogenesis
of the polyglutamine diseases, cystamine is also found to
act in the HD-transgenic mice by mechanisms other than
the inhibition of TGs, such as the inhibition of Caspases
[63], suggesting that this compound can have an additive
eﬀect in the therapy of HD. The pharmacodynamics and the
pharmacokinetics of cystamine, therefore, should be care-
fully investigated in order to conﬁrm the same eﬀectiveness
in patients with neurodegenerative diseases. Another critical
problem in the use of TG inhibitors in treating neurological
diseases relates to the fact that, as previously reported, the
human brain contains at least four TGs, including TG1, 2,
3[ 23], and possibly TG6 [64], and a strong nonselective
inhibitor of TGs might also inhibit plasma Factor XIIIa,
causing a bleeding disorder. Therefore, from a number
of standpoints, it would seem that a selective inhibitor,
which discriminates between TGs, would be preferable to
an indiscriminate TG inhibitor. In fact, although most of
the TG activity in mouse brain, at least as assessed byInternational Journal of Alzheimer’s Disease 5
Table 2: List of polyglutamine (CAG-expansion) diseases.
Disease Sites of neuropathology
CAG triplet number Gene product (Intracellular
localization of protein deposits) Reference
Normal Disease
Corea major or
Huntington’s disease
(HD)
Striatum (medium spiny
neurons) and cortex in late
stage
6–35 36–121 Huntingtin(n, c) [49]
Spinocerebellar Ataxia
Type 1 (SCA1)
Cerebellar cortex (Purkinje
cells), dentate nucleus, and
brainstem
6–39 40–81 Ataxin-1 (n, c) [50]
Spinocerebellar Ataxia
Type 2 (SCA2)
Cerebellum, pontine nuclei,
substantia nigra 15–29 35–64 Ataxin-2 (c) [51]
Spinocerebellar Ataxia
Type 3 (SCA3) or
Machado-Joseph disease
(MJD)
Substantia nigra, globus
pallidus, pontine nucleus,
cerebellar cortex
13–42 61–84 Ataxin-3 (c) [52]
Spinocerebellar Ataxia
Type 6 (SCA6)
Cerebellar and mild brainstem
atrophy 4–18 21–30 Calcium channel subunit (α1A)
(m) [53]
Spinocerebellar Ataxia
Type 7 (SCA7)
Photoreceptor and bipolar
cells, cerebellar cortex,
brainstem
7–17 37–130 Ataxin-7 (n) [54]
Spinocerebellar Ataxia
Type 12 (SCA12) Cortical, cerebellar atrophy 7–32 41–78 Brain-speciﬁc regulatory subunit
of protein phosphatase PP2A (?) [55]
Spinocerebellar Ataxia
Type 17 (SCA17)
Gliosis and neuronal loss in
the Purkinje cell layer 29–42 46–63 TATA-binding protein (TBP) (n) [56]
Spinobulbar Muscular
Atrophy (SBMA) or
Kennedy disease
Motor neurons (anterior horn
cells, bulbar neurons) and
dorsal root ganglia
11–34 40–62 Androgen receptor (n, c) [57]
Dentatorubral-
pallidoluysian atrophy
(DRPLA)
Globus pallidus,
dentatorubral and
subthalamic nucleus
7–35 49–88 Atrophin (n, c) [58]
Cellular localization: c, cytosolic; m, transmembrane; n, nuclear.
an assay that measures the incorporation of radioactive
putrescine (amine donor) into N,N-dimethyl casein (amine
a c c e p t o r ) ,s e e m st ob ed u et oT G 2[ 65], no conclusive data
has been obtained by TG2 gene knock-out experiments
about the involvement of this TG in the development of the
symptoms in HD-transgenic mice [66]. However, a recent
scientiﬁc report showed that cystamine reduces aggregate
formation in a mouse model of oculopharyngeal muscular
dystrophy (OMPD), in which also the TG2 knockdown is
capable to suppress the aggregation and the toxicity of the
mutant protein PABPN1 [67], suggesting this compound as
a possible therapeutic for OMPD.
6. Conclusions
Although many scientiﬁc reports have implicated aberrant
TG activity in Alzheimer’s disease and other neurodegen-
erative diseases, still today we are looking for data which
could deﬁnitely conﬁrm the direct involvement of TGs in the
pathogenetic mechanisms responsible for these diseases. The
useofinhibitorsofTGscouldbethenusefulforexperimental
approaches. To minimize the possible side eﬀects, however,
selective inhibitors of the TGs should be required in the
future. Progress in this area of research may be achieved also
through pharmacogenetic techniques.
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